Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company operates within the biotechnology and oncology therapeutics industries, with a core emphasis on protein engineering and immuno-oncology. BioAtla’s business model is centered on discovering and advancing novel biologics rather than commercial-stage drug sales, and its revenue has historically been derived primarily from collaboration payments and research-related activities rather than product commercialization.
The company’s primary strategic differentiator is its proprietary Conditionally Active Biologics (CAB) platform, which is designed to activate antibodies selectively in the tumor microenvironment while remaining largely inactive in healthy tissue. This approach aims to improve therapeutic efficacy while reducing systemic toxicity. BioAtla was founded in 2007 and transitioned from a private research-focused company to a publicly traded entity following its initial public offering in 2020, which provided capital to expand its clinical development pipeline.
Business Operations
BioAtla’s operations are organized around the discovery, development, and clinical testing of antibody-based drug candidates. Its pipeline includes multiple internally developed oncology programs targeting both solid tumors and hematologic malignancies, with candidates in early- to mid-stage clinical trials. The company does not currently have approved products on the market, and substantially all operating expenses are related to research and development activities, including preclinical studies, clinical trials, and manufacturing of clinical-grade biologics.
The company conducts the majority of its research and development activities internally and through third-party contractors, including contract research organizations and manufacturing partners. BioAtla operates primarily in the United States, with clinical trials conducted at investigational sites that may include international locations. As of publicly available disclosures, the company does not report material revenue from international commercial operations and does not rely on a diversified subsidiary structure for revenue generation.
Strategic Position & Investments
BioAtla’s strategic direction is focused on advancing its CAB-based pipeline through clinical proof-of-concept and positioning select programs for later-stage development, potential partnerships, or licensing transactions. Growth initiatives center on expanding clinical indications for existing candidates and applying the CAB platform to additional biological targets, including immune checkpoint receptors and tumor-associated antigens.
The company has made strategic investments primarily in internal research capabilities and clinical programs rather than external acquisitions. BioAtla has entered into selective collaboration and licensing agreements with larger pharmaceutical companies to validate its technology and offset development costs. Its strategic positioning emphasizes differentiated biologics design rather than scale, with emerging focus areas including next-generation immune modulators and antibody-drug conjugate–related applications. Data regarding long-term capital allocation beyond disclosed clinical programs is limited to public filings and investor disclosures.
Geographic Footprint
BioAtla is headquartered in San Diego, California, a major biotechnology hub within the United States. The company’s executive leadership, research laboratories, and corporate functions are primarily based at this location. Its geographic footprint is otherwise limited, reflecting its status as a clinical-stage organization without global commercial infrastructure.
While BioAtla does not maintain significant physical operations outside the United States, its clinical development activities may extend into international markets through multinational clinical trials conducted in collaboration with external research institutions and clinical sites. The company’s international presence is therefore operational rather than infrastructural, with no disclosed foreign manufacturing or sales offices.
Leadership & Governance
BioAtla is led by a management team with experience in biologics development, oncology research, and public biotechnology company operations. The leadership’s stated philosophy emphasizes scientific rigor, disciplined capital allocation, and leveraging proprietary technology to address unmet medical needs in cancer treatment.
Key executives include:
- Jay M. Short – Chief Executive Officer and Co‑Founder
- Lawrence Steinman – Chief Scientific Officer and Co‑Founder
- Gerry Proehl – Chief Financial Officer
- Kevin E. Wood – Chief Operating Officer
- Robert E. McDowell – Chief Business Officer
The company is governed by a board of directors composed of industry executives, scientific leaders, and experienced public-company directors who oversee corporate strategy, risk management, and compliance with regulatory requirements.